Previous close | 0.35 |
Open | 0.40 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.35 - 8.85 |
52-week range | 0.35 - 56.58 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule
Atara Biotherapeutics ( NASDAQ:ATRA ) First Quarter 2024 Results Key Financial Results Revenue: US$27.4m (up by...